Replication-independent activation of human plasmacytoid dendritic cells by the paramyxovirus SV5 Requires TLR7 and autophagy pathways  by Manuse, Mary J. et al.
Virology 405 (2010) 383–389
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roReplication-independent activation of human plasmacytoid dendritic cells by the
paramyxovirus SV5 Requires TLR7 and autophagy pathways
Mary J. Manuse, Caitlin M. Briggs, Grifﬁth D. Parks ⁎
Department of Microbiology and Immunology, School of Medicine, Wake Forest University, Winston-Salem, NC 27157-1064, USA⁎ Corresponding author. Department of Microbiolog
Medicine, Wake Forest University, Medical Center Blvd
1064, USA. Fax: +1 336 716 9928.
E-mail address: gparks@wfubmc.edu (G.D. Parks).
0042-6822/$ – see front matter © 2010 Elsevier Inc. A
doi:10.1016/j.virol.2010.06.023a b s t r a c ta r t i c l e i n f oArticle history:
Received 3 May 2010
Returned to author for revision 25 May 2010
Accepted 8 June 2010
Available online 6 July 2010
Keywords:
Paramyxovirus
Interferon
Dendritic cellThe paramyxovirus Simian Virus 5 (SV5) is a poor inducer of interferon (IFN) secretion in all cell types tested
so far, including primary epithelial cells and primary human myeloid dendritic cells. SV5 is hypothesized to
limit induction of antiviral responses through control of viral gene expression and production of the V
protein antagonist. Plasmacytoid dendritic cells (pDCs) are known to uniquely express toll-like receptor
(TLR)-7 and are a main producer of IFN-alpha among peripheral blood mononuclear cells in response to
many viruses. Here, we tested whether SV5 would remain a poor inducer of IFN in primary human pDCs. The
efﬁciency of SV5 infection of pDCs could be increased by an increasing multiplicity of infection. pDCs infected
by both live and UV-inactivated SV5 induced large amounts of IFN-alpha secretion and resulted in
upregulation of maturation markers CD80 and CD86. However, IL-6 secretion was not induced by SV5
infection. When TLR7 signaling was inhibited, SV5 induced less IFN secretion and CD80 expression, and there
was a corresponding increase in number of infected cells. Similar effects were seen with inhibitors of cellular
autophagy pathways, suggesting that the SV5 activation of pDC requires access to the cytoplasm and
autophagic sampling of cytoplasmic contents. These results have implications for control of SV5 infections in
vivo and for development of SV5 as a vaccine vector.y and Immunology, School of
., Winston-Salem, NC 27157-
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The parainﬂuenza virus Simian Virus 5 (SV5) is a poor activator of
antiviral responses in human cells (Choppin, 1964; Didcock et al 1999b;
He et al., 2002; Wansley et al., 2005). SV5 encodes the V protein as an
inhibitor of host cell antiviral responses, and this contrasts with many
other paramyxoviruses such as Sendai virus (SeV) and measles virus
(MeV) which encode both a V protein and a family of C proteins which
counteract innate responses (Lamb and Parks, 2007). The poor
activation of host cell responses by SV5 infection is thought to be
largely due to twomain factors: the actions of the viral V protein and the
control of viral RNA synthesis. A major function of the SV5 V protein is
the inhibition of IFN signaling, which occurs through V-mediated
targeting of signal transducer and activator of transcription 1 (STAT1)
for ubiquitylation and degradation (Didcock et al., 1999a). The SV5 V
protein also blocks activation of the IFN-beta promoter during virus
infection or following transfection of dsRNA (Andrejeva et al., 2004; He
et al., 2002). TheparamyxovirusVprotein inhibits IFN-beta inductionby
targeting the IFN-inducible RNA helicase encoded by the melanoma
differentiation-associated gene 5 (mda-5; Andrejeva et al., 2004). By
contrast, the alternative RNA helicase retinoic acid-inducible gene I(RIG-I) does not appear to be inhibited by V protein (Childs et al., 2007).
V protein is thought to also act as a decoy substrate for kinases that
activate IFN regulatory factor 3 (Lu et al., 2008). In support of these V
functions, a recombinant SV5 that encodes a truncatedVprotein lacking
the highly conserved cys-rich domain is a potent activator of IFN-beta
and proinﬂammatory cytokine synthesis (He et al., 2002).
A second major factor contributing to limited activation of cellular
responses is the ability of SV5 to control levels and types of viral RNA
generated during replication. This is evident from our ﬁnding that an
SV5 mutant with substitutions in the genomic promoter overexpresses
viral RNA and also induces IFN and cytokines through RIG-I pathways,
even though this mutant expresses a functional V protein (Manuse and
Parks, 2009). Similarly, potent antiviral responses are inducedby an SV5
P/Vmutant which overexpresses viral RNA (Wansley and Parks, 2002),
but importantly, expression of theWT P subunit of the viral polymerase
restores normal levels of viral gene expression and reduces host cell
responses (Dillon and Parks, 2007). Together, these data support a
model whereby SV5 infection fails to activate antiviral responses during
a robust replication cycle, except under conditions where V protein is
defective or when synthesis of viral RNA components is elevated over a
threshold. Thismodel raises thequestion ofwhether SV5would still be a
poor inducer of antiviral responses in cells that sense virus by
mechanisms that are independent of virus replication.
Dendritic cells (DCs) play a critical role in sensing viral infections to
activate both innate and adaptive immune responses. Two major DC
subsets exist within human peripheral blood (Shortman and Liu, 2002):
384 M.J. Manuse et al. / Virology 405 (2010) 383–389myeloiddendritic cells (mDCs) andplasmacytoiddendritic cells (pDCs).
mDCs are very efﬁcient at phagocytosis and antigen presentation that
can result in strong activation of T cells (Banchereau et al., 2000; Reis e
Sousa, 2001). SV5 can establish highly productive infections of primary
human mDC, and similar to epithelial cells, these infected mDC do not
secrete high levels of IFN or cytokines (Arimilli et al., 2006, 2007).
Consistent with this ﬁnding, SV5-infectedmDCs are poor activators of T
cell function in vitro (Arimilli et al., 2006).
By contrast to mDC, pDCs are much less efﬁcient at phagocytosis,
antigen presentation, and activation of T cells. Instead, this DC subset
responds to virus exposure by rapidly producing abundant amounts of
IFN-alpha (Barchet et al., 2005; Liu, 2005). pDC differ frommDC in their
proﬁle of toll-like receptor (TLR) expression (Blasius and Beutler, 2010).
WhilemDCs express TLR1, 2, 4, 5, 6, and 8, pDCs have high expression of
TLR7 and TLR9 (Shortman and Liu, 2002), which recognize ssRNA and
CpG DNA, respectively (Bauer et al., 2001; Diebold et al., 2004). pDCs
have been demonstrated to produce IFN-alpha in response to virus by
mechanisms that are either dependent or independent of virus
replication. For example, pDCs produce IFN-alpha in response to herpes
simplex virus-2, West Nile virus, and hepatitis C virus independent of
viral replication (Liang et al., 2009; Lund et al., 2003; Silva et al., 2007).
On the other hand, IFN-alpha secretion from pDCs infected with
negative strand viruses such as vesicular stomatitis virus (VSV),
respiratory syncytial virus (RSV), and Sendai virus has been shown to
depend on replication (Hornung et al., 2004; Lee et al., 2007; Waibler
et al., 2008). Consistent with virus replication in the cytoplasm, the
cellular autophagymachinerywhichdirects cytoplasmic contents to the
endosome is required for Sendai virus and VSV replication-dependent
activation of pDC (Lee et al., 2007).
Given that WT SV5 is a poor inducer of host cell cytokine synthesis
during replication in both epithelial and mDC cultures, we have
addressed the question of whether SV5 will also be a poor inducer of
IFN from pDC which can detect virus infections by a replication-
independent mechanism. Using primary cultures of human pDC, our
results support amodelwhereby IFN-alpha induction from infectedpDC
is independent of virus replication but is dependent on signaling
through TLR7 and autophagy pathways. Thus, SV5 activation of human
pDC differs from other negative strand viruses since it is not dependent
on virus replication but involves signaling through TLR7 and autophagy
pathways.
Results
SV5 can productively infect human pDCs
Since human pDCs represent only∼0.5% of PBMCs (Jing et al., 2009),
pDCswere isolated fromwhole blood PBMCs by positive selection using
anti-CD304 antibody-conjugated microbeads. It is known that pDCs
express cell surface markers that are distinct from that seen with
myeloid DCs (Shortman and Liu, 2002). As shown in Fig. 1A, our pDC
preparations displayed the previously deﬁned proﬁle of high CD123
(IL-3 receptor) expression and lack of CD11c expression. This contrasted
with the proﬁle ofmyeloid DCs, which express high levels of CD11c and
very low levels of CD123 (Fig. 1A).
To determine the extent to which SV5 could infect pDCs, cells were
mock infected or infected at anMOI of 10, 50, or 100 PFU/cell with SV5
that was engineered to encode EGFP as an additional gene between HN
and L (Arimilli et al., 2007). As shown in Fig. 1B, a low number of pDCs
expressedEGFPwhen infectedat anMOIof10, but thiswas substantially
increased by an increasing MOI. The percentage of pDCs that were
positive for SV5-derived EGFP expression was quantiﬁed for ﬁve
different donors by ﬂow cytometry (Fig. 1C). At an MOI of 10, on
average ∼15% of the pDC population was EGFP positive, but an MOI of
100 resulted in an average of 35% of the pDCs being positive for EGFP
expression. In addition, de novo viral NP and M protein expression was
detected by metabolic labeling and immunoprecipitation of extractsfrom cells infected with live SV5-EGFP but not with UV-inactivated
SV5-EGFP (data not shown). These data demonstrate that SV5 can
productively infect pDCs and that a greater number of cells can be
infected with increasing MOI.Live andUV-treated SV5 induce similar IFN-alpha secretion andmaturation
marker expression from pDC
Previous results have shown that some paramyxoviruses such as
measles virus and respiratory syncytial virus block activation of human
pDC responses (Schlender et al., 2005). To determine the response of
human pDCs to SV5 infection, cells were mock infected, infected with
live SV5-EGFP or UV-inactivated SV5-EGFP at an MOI of 100, or treated
with the TLR7 agonist imiquimod as a positive control. Twenty-four
hours later, media were analyzed by ELISA for levels of IFN-alpha. As
shown in Fig 2A, pDC isolated from three different donors responded to
the positive control TLR-7 agonist imiquimod by secreting large
amounts of IFN-alpha. Similarly, infection with live SV5-EGFP induced
very high levels of IFN-alpha from pDCs, but this same level of IFN was
also seen using UV-inactivated virus. The kinetics of IFN-alpha secretion
was nearly identical for pDC treated with live and with UV-inactivated
SV5-EGFP (Fig. 2B), and this lagged substantially from the rapid
induction by imiquimod. The level of IFN-alpha secretion was not
altered by increasing MOI above 10 since very similar levels were
detected using live virus at MOIs of 10, 50, and 100 but also by
UV-inactivated virus. Thus, while increasing MOI leads to increased
numbers of infected cells (Fig. 1), it has little effect on levels of IFN-alpha
production (Fig. 2).
In Fig. 2, each symbol represents data from cells obtained from an
individual donor. It is noteworthy that in Fig. 2, for a given treatment,
there was some variability among donors in the level of IFN-alpha
induction. However, for each donor, the relative IFN-alpha induction
from pDC treated with live virus, UV-treated virus, and imiquimod was
remarkably consistent.
While myeloid DC are thought to be the most potent antigen
presenting cells, pDC can also increase expression of cell surface
costimulatory markers CD80 and CD86 (Banchereau et al., 2000; Reis e
Sousa, 2001). As shown in Fig. 3 for three donors, infection of pDCswith
SV5-EGFP resulted in upregulation of CD80 (panel A) and CD86
(panel B) above that seen for mock-infected cells (indicated by the
dotted line). Increases in CD80 expression were consistently seen but
werenot statistically signiﬁcant compared tomocksamples. By contrast,
changes in CD86were highly signiﬁcant (pb0.005). Similar to IFN-alpha
induction, maturation marker expression did not differ between live or
UV-inactivated virus.
Interestingly, although exposure of human pDC to SV5 induced
both IFN-alpha secretion and upregulation of maturation markers
(Figs. 2 and 3), there was no signiﬁcant increase in the secretion of
IL-6 (Fig. 4). This result is similar to the IFN and cytokine responses
found for inﬂuenza virus infection of mouse pDC which differed from
that seen with CpG treatment (Iparraguirre et al., 2008).
We have previously described two SV5 mutants that are potent
inducers of IFN secretion through production of dsRNA and activation of
RIG-I signaling (Manuse and Parks, 2009, 2010; Wansley and Parks,
2002). As shown in Fig. 5, pDC infectedwith thesemutants also induced
high levels of IFN-alpha. For some donors (e.g., donors 1 and 2), the
leader mutant and P/V mutant consistently induced slightly lower and
slightly higher IFN levels compared to WT SV5-EFGP, respectively, but
these levels were not substantially different. These data indicate that in
pDCs, WT SV5 induces approximately the same level of IFN secretion as
SV5mutantswhich potently induce IFN through replication-dependent
pathways (Manuse and Parks, 2009). Taken together, these results
indicate that WT SV5 is a potent inducer of IFN-alpha and surface
maturationmarker expression in pDCs and that activation of these cells
does not require virus replication.
Fig. 1. SV5 productively infects pDC in vitro. (A) Markers on plasmacytoid DCs. pDCs were isolated by positive selection from PBMCs fromwhole human blood using CD304microbeads.
After overnight culturing, cells were stained for surface expression of CD123 and CD11c (bold lines) or with an isotype control (thin lines) before analysis by ﬂow cytometry. For
comparison, monocyte precursors were isolated from PBMCs from whole human blood by positive selection using CD14 microbeads, and myeloid DC were generated as described
previously (Arimilli et al., 2007) before staining for surface markers in parallel. (B) pDCs were mock infected, infected at an MOI of 10, 50, or 100 with SV5-EGFP or infected with UV-
inactivated SV5-EGFP at anMOI of 100. Phase (top panel) or ﬂuorescence (bottompanel)micrographswere taken at 24 h pi. (C) pDCs frommultiple donors (each donor is represented by
a symbol) were mock infected or infected at an MOI of 10, 50, or 100 with SV5-EGFP. At 24 h pi, the number of EGFP-positive cells was quantiﬁed by ﬂow cytometry. Bar represents the
average of ﬁve donors for each MOI.
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pDC can sense viral infections through TLR7 or TLR9, both of which
exist within pDC endosomal compartments (Lee et al., 2003; Mark
et al., 2004). Since SV5 is an RNA virus, we hypothesized that the RNA-
sensing TLR7 pathwaywas involved in pDC responses to infection and
that inhibitors of endosomal acidiﬁcation would block responses to
SV5. To test this hypothesis, pDCs were pre-treated with the
endosomal inhibitor chloroquine and then mock infected or infected
with the live or UV-treated SV5-EGFP at an MOI of 100. Twenty-four
hours later, media were analyzed by ELISA for IFN-alpha. As shown in
Fig. 6A for three independent donors, live and UV-inactivated
SV5-1EGFP induced ∼6,000 pg/ml of IFN-alpha (open symbols), and
this activation was reduced to ∼1000-2000 pg/ml by chloroquine
treatment (closed symbols).
To test the role of TLR7 in pDC activation by SV5, cells were treated
prior to infection with IRS661, an oligonucleotide inhibitor that has
been shown to be speciﬁc for TLR7 signaling (Wang et al., 2006). In
cells treated for 30 min with the inhibitor (closed symbols, Fig. 6B),
levels of IFN-alpha induced by live SV5-EGFP (open symbols) were
substantially reduced, while only background levels were seen with
UV-inactivated virus or with stimulation by imiquimod (Fig. 6B).
Similar results were seen for maturation markers, where addition of
the TLR7 inhibitor gave a signiﬁcant reduction in levels of cell surface
CD80 surface expression after exposure to SV5 (Fig. 6C). Together
these results with two different inhibitors support the hypothesis that
SV5 activates pDC through TLR7 signaling.The number of pDCs that were positive for SV5-derived EGFP
expression increased upon inhibition of TLR signaling by either IRS
661 (Fig. 7A) or chloroquine (Fig. 7B). With IRS661 treatment, the
effect of TLR7 inhibition on number of infected cells was dramatic,
with the number of infected cells increasing from 25% to 50% EGFP
positive, while chloroquine treatment had a lesser effect. Additionally,
the level of viral gene expression as calculated by the mean
ﬂuorescent intensity of the EGFP-positive population was also
enhanced when TLR7 signaling was inhibited (data not shown).
These data indicate that the SV5 activates pDCs through TLR7
signaling and that inhibition of TLR7 decreases IFN production and
increases both the percentage of infected cells as well as the level of
viral gene expression.
Inhibitors of autophagy reduce SV5 activation of pDC responses
Activation of SV5-infected pDCs could result from direct exposure of
virus to endosomal TLR7 prior to fusion with the plasma membrane.
Alternatively, previous results have shown that VSV and Sendai virus
activate pDC in a replication-dependent manner after access to the
cytoplasm, and the viral RNAs are thought to be targeted to the
endosome by autophagy since activation is blocked by autophagy
inhibitors (Lee et al., 2007). To determine the role of autophagy in
SV5-mediated pDC activation, cells were mock treated or treated with
the autophagy inhibitors wortmanin (WM) and 3-methyladenine
(3MA) at concentrations used in previous studies (Lee et al., 2007),
and levels of SV5-induced IFN-alpha were determined. As shown in
Fig. 2. IFN-alpha production from SV5-infected pDCs. (A) IFN induction. pDCs from
three donors (each is represented by a different symbol) were mock infected, infected
with live SV5-EGFP or UV-treated SV5-EGFP at an MOI of 100, or treated with 1 μg/ml
imiquimod as a positive control. At 24 h pi, supernatant was harvested and analyzed by
ELISA for level of IFN-alpha. p values for SV5 and UV-treated SV5 are shown. (B) Time
course of IFN induction. pDCs from one representative donor were treated as described
for panel A. At the indicated hours pi, supernatant was harvested and analyzed by ELISA
for levels of IFN-alpha. (C) Effect of MOI on IFN induction. pDC were infected at the
indicated MOIs and treated as described in panel A. Levels of IFN-alpha secretion were
determined at 24 h pi. In panels A and C, bars represent mean levels for the three
donors. For panel C, data for all conditions had a signiﬁcance of pb0.004 when
compared to mock sample.
Fig. 3. Increased maturation marker expression on SV5-infected pDCs. Human pDCs
from three donors (each represented by a different symbol) were mock infected,
infected with live SV5 or UV-inactivated SV5 at an MOI of 100, or treated with 1 μg/ml
imiquimod as a positive control. At 24 h pi, cells were harvested and surface labeled for
CD80 (panel A) and CD86 expression (panel B). pDCs were analyzed by ﬂow cytometry
and results are expressed as fold mock mean ﬂuorescent intensity (MFI) of maturation
marker expression. The dashed line indicates the level of expression for mock-infected
cells set at one. The average of three donors for each condition is represented by a bar.
Mean level of maturation marker upregulation for imiquimod treated pDCs is shown as
26.6. For panel B, data from SV5 and UV-treated SV5 samples had p values of 0.0008 and
0.005, respectively.
Fig. 4. Induction of IL-6 from human pDC by a TLR7 agonist but not by SV5. Human pDC
were treated as described in the legend to Fig. 3, and at 24 h post-infection levels of
secreted IL-6 were determined by ELISA. The average of three donors for each condition
is represented by a bar.
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with SV5-EGFP, but most importantly VSV-mediated IFN secretion was
blocked by prior treatment with both WM and 3-MA as reported
previously (Lee et al., 2007). Similarly, IFN induced by live SV5-EGFP or
UV-inactivated virus was dramatically reduced by treatment with WM
or 3-MA. These results are important as they demonstrate that a virus
(e.g., SV5) which activates pDC IFN responses by a replication-
independentmechanism requires the same cellular autophagymachin-
ery as a virus (e.g., VSV) that activates through replication-dependent
pathways.
Discussion
Host cell responses to viral infections can be initiated by receptors
that detect and respond to viral replication products. For example, the
cytoplasmic helicases RIG-I andMDA-5 can detect viral RNA replication
products and initiate synthesis of IFN and other antiviral cytokines
(Childs et al., 2007; Yoneyama et al., 2005). In all of the human cell types
which we have examined so far including epithelial, ﬁbroblast, and
mDC, SV5 establishes highly productive infections with only minimal
activation of antiviral responses (Wansley and Parks, 2002; Arimilli
et al., 2006). The only example of SV5 strongly inducing cytokine
secretion from human cells is when the virus encodes an altered Vprotein (Dillon et al., 2007; He et al., 2002;Wansley and Parks, 2002) or
whenviral RNAsynthesis is elevatedbymutations in viralproteinsother
than V protein (Manuse and Parks, 2009; Young et al., 2006). Thus, for
the SV5 P/V and Leader mutants described previously, antiviral
responses require virus replication and are mediated in large part by
RIG-I signaling pathways (Manuse and Parks, 2010). Viral infections can
also be detected by mechanisms that are not dependent on virus
replication, including interactions with TLRs (Boehme and Compton,
2004). The overall goal of this work was to address the question of
whether SV5would also be a poor inducer of IFN frompDCwhichutilize
TLR7 to respond to viruses throughmechanisms that are not dependent
on virus replication.
In primary human pDCs, WT SV5 activated very potent IFN-alpha
secretion, but importantly this was not dependent on virus replication.
This was evident by our ﬁndings that IFN-alpha secretion: (1) was
similar betweenpDCexposure toUV-inactivatedand live infectiousSV5,
Fig. 5. Activation of IFN-alpha secretion by SV5 RNA synthesis mutants. pDC were
infected with SV5-EGFP or with the SV5 mutants containing substitutions in the leader
promoter (Le) or the P/V gene (P/V). Alternatively, cells were treated with the TLR7
ligand imiquimod. At 24 h pi, levels of secreted IFN-alpha were determined by ELISA.
Results are from two separate experiments with two donors. Data for two donors with
similar levels of IFN are shown in the top panel. Data from a donor with low levels of IFN
are graphed in the lower panel.
Fig. 6. Inhibitors of TLR7 decrease IFN-alpha secretion and CD80 expression in
SV5-infected pDC. (A) Effect of chloroquine. pDCs from three donors were mock treated
(control samples) or pre-treated with 2.5 μg/ml of chloroquine (ﬁlled symbols). Cells
were then mock infected or infected with live or UV-inactivated SV5 at an MOI of 100.
Twenty-four hours pi, supernatant was harvested and analyzed for levels of IFN-alpha
by ELISA. (B) Effect of TLR7 inhibitor. pDCs from three donors were pre-treated with
2 μM IRS661 (closed symbols) or were left untreated (open symbols) for 30 min. Cells
were then mock infected or infected as described for panel A. Twenty-four hours pi,
supernatant was analyzed for IFN-alpha by ELISA. (C) Effect of TLR7 inhibitor on
maturation markers. Cells were treated as described in panel B and at 24 h pi cells were
stained for CD80 surface expression and analyzed by ﬂow cytometry. Results are
expressed as fold mock mean ﬂuorescent intensity (MFI) of CD80 expression. The
dashed line indicates the level of expression for mock-infected cells set at one. The
average of three donors for each condition is represented by the bar.
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similar between WT SV5 and SV5 mutants that overexpress viral gene
products. This latter ﬁnding is important support that SV5 activation of
antiviral responses in human pDC is not dependent on virus replication,
aswas shownpreviously for responses to thesemutants in epithelial cell
types (Manuse andParks, 2009, 2010). Toour knowledge, this is theﬁrst
human cell type in which WT SV5 infection induces a strong IFN
response. This work highlights the correlation between the type of
pattern recognition receptor expressed in a cell (e.g., TLR7) and the
extent to which host cell responses are activated during viral infection.
Inhibitor studies indicate that TLR7 played an important role in
responding to both live and UV-inactivated SV5. Since TLR7 senses
ssRNA, it is likely that this pattern recognition receptor is directly
detecting the viral genome. The currentmodel for SV5 entry depends on
fusion at the cell surface resulting in the deposition of the viral genome
into the cytoplasm of the cell (Lamb, 1993). This raises the question of
how the nucleocapsid-bound viral genome is detected by TLR7 which
exists within endosomes. One possibility is that pDCs havemechanisms
for rapid endocytosis from the plasma membrane such that some virus
particles are endocytosed as an alternative outcome to fusion with the
plasmamembrane to deposit the nucleocapid in the cytoplasm. At least
some live virus particles are able to enter the cytoplasm and begin viral
gene transcription as evidenced by GFP expression, especially at higher
multiplicities of infection. Interestingly, very similar levels of IFN-alpha
secretion are seenwith lowandhighMOI infections,which indicate that
there may be a low threshold for number of genomes needed for TLR7
activation.
Alternatively, viral genomes that are deposited into the cytoplasmby
fusion may gain access to endosomal TLR7 by means of autophagy, a
cellular process that delivers cytoplasmic components to intracellular
vesicles including lysosomes and endosomes (Mizushima, 2009).
Autophagy has been implemented during virus infection by regulating
programmed cell death and in controlling antiviral responses to
infection (Orvedahl, and Levine, 2009). Although we have not carried
out parallel experiments with VSV in this study, previous work hasdemonstrated that VSV requires replication to induce IFN production
frompDCs (Iwasaki, 2007; Lee et al., 2007). Furthermore, VSV induction
of IFN-alpha is through autophagy-dependent mechanisms (Lee et al.,
2007). Our results differ from previous reports with Sendai virus and
VSV by demonstrating that SV5 which activates pDC independent of
replication also requires autophagy pathways.
While only a few studies of paramyxovirus infection of human pDCs
have been previously reported, the published data revealed differences
between viruses in the degree andmechanism of pDC activation. In one
report, respiratory syncytial virus (RSV) strain A2 and human
metapneumovirus induced IFN-alpha secretion from infected pDCs
but also blocked a further increase in IFN production upon challenge
with a TLR9 agonist (Guerrero-Plata et al., 2006). Other investigators
reported that pDCs are not activated for IFN secretion by exposure to
either the A2 strain or clinical isolates of RSV or by measles virus,
whereas the RSV strain Long induced large amounts of type I IFN
(Schlender et al., 2005). Similarly, SeV induces IFN-alpha from pDC in a
replication-dependent mechanism (Lee et al., 2007), which contrasts
with our results here for SV5. Together, these studies illustrate different
mechanisms for IFN induction employed by members of this diverse
family of viruses. Futureworkwill focus onwhether this is a reﬂection of
Fig. 7. TLR7 inhibition increases the number of SV5-infected pDCs. pDCs from three
different donors (each represented by a different symbol) were left untreated
(open symbols) or pre-treated (closed symbols) with 2 μM IRS661 (panel A) or
2.5 μg/ml chloroquine (panel B). Cells were then infected at an MOI of 100 with
SV5-EGFP and at 24 h pi were harvested and analyzed for EGFP expression by ﬂow
cytometry. The average of three donors for each condition is represented by the bar. Fig. 8. Autophagy inhibitors block IFN-alpha secretion from SV5-infected pDCs. Human
pDCs from three different donors were left untreated (black bars) or pre-treated with
Wortmanin (gray bars) or 3-MA (white bars). Cells were thenmock infected or infected
with live or UV-inactivated SV5 at an MOI of 100. Twenty-four hours pi, supernatant
was harvested and analyzed for levels of IFN-alpha by ELISA.
388 M.J. Manuse et al. / Virology 405 (2010) 383–389the different mechanisms paramyxoviruses employ to counteract host
cell responses.
When TLR7 pathways were inhibited, SV5-infected pDC secreted less
IFN-alpha as expected, but therewas also a higher percentage of cells that
were positive for GFP expression. This may have resulted from decreased
IFN-alpha signaling, which is known to upregulate many genes that
inhibit virus replication. However, IFN signaling should not be a factor in
SV5-infected cells due to actions of the V protein in targeting STAT1 for
degradation (Didcock et al., 1999b). V-mediated STAT1 degradation is
rapid and can even be catalyzed by V that is contained within the
incoming virion particle (Precious et al., 2007). Thus, increased SV5
replication in the presence of a TLR7 inhibitor is not likely to be due to
changes in IFN signaling. As an alternative, TLR7 inhibition may increase
virus replication due to inhibition of intracellular pathways that are
directly activated by TLR7 signaling. This proposal is consistent with the
ﬁnding that TLR7-mediated induction of antiviral genes does not require
IFN signaling but rather TLR7 can directly induce antiviral gene products
(Domizio et al., 2009). Thus,while the SV5Vprotein canblock the effect of
IFN-alpha production by infected cells, TLR7 may still inhibit SV5
replication through a direct intracellular activation of antiviral pathways
that is independent of signaling.
Our previous studies with animal models of SV5 infection indicate
that despite being a poor inducer of IFN in tissue culture cells, virus
growth in vivo is limited and virus is cleared from the respiratory tract
by ∼7 days post-infection (Capraro et al., 2008). Thus, at least in the
ferret model SV5 does not establish long term infections of the
respiratory tract contrary to what is predicted by its behavior in tissue
culture cells. Our ﬁnding that pDCs produce high levels of IFN in
response to SV5 by a replication-independent mechanism provides
some insight into possible limitations on growth in vivo. We propose
thatpDC recruited to the site of SV5 infection respond toprogenyvirions
by producing high levels of IFN-alpha, which in turn limits SV5 growth
and aids in virus clearance by immune mechanisms.Materials and methods
Cells, viruses, and reagents
Plasmacytoid dendritic cells (pDC) were prepared from human
peripheral blood mononuclear cells harvested as described previously
(Arimilli et al., 2006). Brieﬂy, whole blood from healthy donors was
subjected to Ficoll–Hypaque (Isolymph, CTL, Deer Park, NY) density
gradient centrifugation. pDCs were isolated by magnetic activated cell
sorting (MACS) using microbeads containing anti-CD304 (Miltenyi
Biotech). Cells were cultured in RPMI (Lonza) with 10% FBS (heat
inactivated), 1% penicillin/streptomycin, 1% non-essential amino acids,
1 mM sodium pyruvate, 2 mM L-glutamine, and 10 mM HEPES, with
50 ng/ml interleukin (IL)-3 (Miltenyi Biotech, Auburn, CA) to promote
cell viability.
Recombinant SV5 encoding the enhanced green ﬂuorescent
protein (SV5-EGFP) as an additional gene between HN and L was
generated from cDNA as described previously (Arimilli et al., 2007).
Viruses were grown in MDBK cells and puriﬁed by centrifugation
through a 25% glycerol cushion (Capraro et al., 2008).Infection, inhibitors, IFN ELISA, and cell surface labeling
Cells were mock infected or infected in suspension at the MOIs
indicated in the ﬁgure legends. As positive control for TLR7 activation,
cells were treated with gardiquimod (InvivoGen, San Diego, CA) at a
concentration of 1 μg/ml at the time of infection. The TLR7 inhibitor
IRS661 is an oligonucleotide with the sequence 5′-TGCTTGCAAGCTTG-
CAAGCA-3′ (Pawar et al., 2007) andwas added 30 min prior to infection
at a concentration of 2.8 μM. Chloroquine (Sigma) was used at a
389M.J. Manuse et al. / Virology 405 (2010) 383–389concentration of 2.5 μg/ml. Wortmanin and 3-methyladenine (3-MA)
were added 10 min prior to infection at 10 nM and 1 mM, respectively.
IFN-alpha and interleukin-6 in cell culture supernatant were
measured by an ELISA (PBL Biosciences, Piscataway, NJ), and values
were normalized to 2×105 cells in order to compare between
experiments. To detect cell surface markers and EGFP expression, cells
were stained with the following conjugated monoclonal antibodies:
CD11c, CD123, CD80, and CD86 (BDPharmigen, SanDiego, CA). Samples
were analyzed on a FACScan instrument using Cell Quest software
(BentonDickinson, SanDiego, CA). Statistical analysis of datawas by the
Student's t-test type two-tailed method.
Microscopy
Microscopy was carried out as described previously using a Nikon
Eclipsemicroscope and a 20× lens (Manuse and Parks, 2009). Phase and
ﬂuorescent images were captured using a QImaging digital camera and
processed using QCapture software (QImaging, Surry, BC, Canada).
Exposure times were set manually to be constant between samples.
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